OctoPlus

Past Funding Woes, Thallion Gets Cash, E. Coli Drug Partner.
BIOWORLD Today; 12/21/2009; 1350 words; ...common stock at an exercise price of 50.9 cents per share. o OctoPlus NV, of Leiden, the Netherlands, has completed an equity...future, the company said. In connection with the offering, OctoPlus said that it has obtained a new credit facility at more favorable...

Dutch OctoPlus raises EUR 4m in equity placing.
ADP News Netherlands; 12/18/2009; 388 words; ...2009 - Dutch biopharmaceutical company OctoPlus NV (AMS:OCTO) has raised EUR 4 million...new credits of up to EUR 2 million, OctoPlus also said on Friday. The new financing will enable OctoPlus to grow further its drug delivery service...

Dutch OctoPlus confirms 2009 outlook.
ADP News Netherlands; 11/9/2009; 342 words; ...2009 - Dutch biopharmaceutical company OctoPlus NV (AMS:OCTO) reiterated today its...disclose concrete figures. According to OctoPlus, the profit was a result of cost savings...cashflow in the second half of the year. OctoPlus signed in September a pharmaceutical...

Biolex Raises $30M In Series C To Advance Hepatitis C Drug.
BIOWORLD Today; 11/3/2009; 1197 words; ...the recombinant interferon-alpha which is combined with the PolyActive controlled-release drug delivery technology from OctoPlus NV to make Locteron. The companies have a co-development partnership dating back to early 2005 aimed at improving the formulation...

Clinic Roundup.
BIOWORLD Today; 11/3/2009; 1135 words; ...respiratory infections, rheumatoid arthritis and HIV. o Biolex Therapeutics Inc., of Pittsboro, N.C., and partner OctoPlus NV, of Leiden, the Netherlands, reported positive initial results from its ongoing SELECT (Safety and Efficacy of Locteron...